Global Market Study on Compounding Pharmacies: Oral Medication Anticipated to Remain the Most Favored Drug Type Through 2025 According to the latest market report published by Persistence Market Research titled ‘Compounding Pharmacies Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global compounding pharmacies market is expected to expand at a CAGR of 7.5% during the forecast period 2017-2025. The revision in the market size and forecasts have been carried out taking into account the impact of various macroeconomic indicators and other industrybased demand-driving factors, as well as the recent developments of key market participants. The global compounding pharmacies market is projected to expand at a healthy CAGR of 7.5% in terms of value during the forecast period, revised from the previous CAGR of 4.4%, due to factors such as increasing medicinal droughts of prescription medicine across the globe, regarding which Persistence Market Research offers useful insights in detail in this report. The primary factors driving revenue growth of the global compounding pharmacies market are increasing medicinal droughts of prescription medicine, growing demand for HRT drugs, and increase in demand for topical products – these factors will upsurge the growth of the compounding pharmacies market in the coming years. Increasing restricted formulations and unsafe compounding practices are some of the factors that will restrain the growth of the compounding pharmacies market over the forecast period. Browse Full Research Report: https://www.persistencemarketresearch.com/market-research/compoundingpharmacies-market-112017.asp Segmental Forecast of the Global Compounding Pharmacies Market The market is segmented based on product type, application type, therapeutic area and region. On the basis of product type the market has been segmented as oral medication, topical medication, mouthwashes and suppositories. By product type, the oral medication segment is expected to remain the largest segment, registering a CAGR of 9.5% in terms of value over the forecast